Excelsior Biopharma Inc. (TPEX:6496)
Taiwan · Delayed Price · Currency is TWD 25.00
+0.10 (0.40%)
Aug 19, 2026, 1:30 PM CST
Excelsior Biopharma Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -206.58 | -183.17 | -98.71 | -91.01 | -33.76 | -15.65 |
Depreciation & Amortization | 70.15 | 71.68 | 70.96 | 46.22 | 26.06 | 28.65 |
Loss (Gain) From Sale of Assets | -3.73 | 0.65 | - | - | - | - |
Loss (Gain) From Sale of Investments | - | - | - | - | - | 0.21 |
Loss (Gain) on Equity Investments | -3.43 | -2.18 | -0.25 | - | - | - |
Stock-Based Compensation | 0.33 | 0.28 | 0.33 | 0.26 | 0.04 | - |
Provision & Write-off of Bad Debts | 0.34 | -2.56 | 2.25 | 0.98 | -3.67 | 4.47 |
Other Operating Activities | 3.4 | -1.8 | 2.81 | 6.75 | 0.78 | 5.53 |
Change in Accounts Receivable | -27.38 | -45.81 | -30.53 | -27.17 | 82.26 | -35.87 |
Change in Inventory | -32.7 | 17.75 | -85.65 | -28.7 | 16.02 | 71.88 |
Change in Accounts Payable | 15.59 | -38.78 | 42.43 | -16.92 | -49.79 | -18.52 |
Change in Other Net Operating Assets | 36.22 | 45.22 | -3.44 | -25.15 | -32.46 | 15.13 |
Operating Cash Flow | -147.79 | -138.72 | -99.8 | -134.75 | 5.49 | 55.82 |
Operating Cash Flow Growth | - | - | - | - | -90.17% | -89.28% |
Capital Expenditures | -14.6 | -36.95 | -257.15 | -35.66 | -7.78 | -2.88 |
Sale of Property, Plant & Equipment | 3.76 | 2.25 | - | - | - | - |
Investment in Securities | 11.45 | 11.45 | -55.5 | 199.74 | -200 | -6.01 |
Other Investing Activities | -0.37 | -1.15 | 5.62 | -17.47 | 8.54 | -1.8 |
Investing Cash Flow | 0.24 | -24.4 | -307.03 | 146.62 | -199.24 | -10.68 |
Short-Term Debt Issued | - | 159.61 | 0.01 | 0.01 | - | - |
Long-Term Debt Issued | - | - | 110 | - | - | - |
Total Debt Issued | 259.61 | 159.61 | 110.01 | 0.01 | - | - |
Short-Term Debt Repaid | - | - | -0.01 | -0.01 | - | - |
Long-Term Debt Repaid | - | -51.97 | -53.98 | -317.23 | -13.73 | -12.64 |
Total Debt Repaid | -111.01 | -51.97 | -53.99 | -317.24 | -13.73 | -12.64 |
Net Debt Issued (Repaid) | 148.6 | 107.64 | 56.02 | -317.23 | -13.73 | -12.64 |
Repurchase of Common Stock | - | - | - | - | - | -23.74 |
Common Dividends Paid | - | - | - | - | - | -46.67 |
Other Financing Activities | -0.27 | 0.74 | 0.98 | - | - | - |
Financing Cash Flow | 148.33 | 108.38 | 56.99 | -317.23 | -13.73 | -83.04 |
Net Cash Flow | 1 | -54.74 | -349.84 | -305.36 | -207.49 | -37.9 |
Free Cash Flow | -162.38 | -175.67 | -356.95 | -170.41 | -2.3 | 52.95 |
Free Cash Flow Growth | - | - | - | - | - | -89.60% |
Free Cash Flow Margin | -17.33% | -19.56% | -41.41% | -22.09% | -0.34% | 3.96% |
Free Cash Flow Per Share | -3.51 | -3.81 | -7.74 | -3.71 | -0.05 | 1.14 |
Levered Free Cash Flow | -79.99 | -104.35 | -311.04 | -139.51 | 4.43 | 59.32 |
Unlevered Free Cash Flow | -74.36 | -99.49 | -306.02 | -135.53 | 7.15 | 62.16 |
Cash Interest Paid | 7.65 | 7.65 | 7.96 | 1.36 | 0.88 | 1.12 |
Cash Income Tax Paid | 12.4 | 12.4 | 8.36 | 8.38 | 8.28 | 3.46 |
Change in Working Capital | -8.27 | -21.62 | -77.19 | -97.95 | 16.03 | 32.61 |